AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

Why It Matters

The acquisition gives Lilly a differentiated shingles vaccine and expands AAHI’s commercial reach, while the retained licensing rights open revenue streams across multiple therapeutic areas.

Key Takeaways

• Lilly acquires Curevo’s CRV‑101 shingles vaccine
• CRV‑101 uses AAHI’s SLA‑SE adjuvant for stronger T‑cell response
• SLA‑SE adjuvant retains licensing rights for other vaccines and cancer therapies
• Next‑gen adjuvants aim to improve tolerability and efficacy across indications
• AAHI’s nonprofit model accelerates global access to advanced vaccine technologies

Pulse Analysis

The emergence of next‑generation adjuvants like AAHI’s SLA‑SE marks a pivotal shift in vaccine design, moving beyond traditional aluminum‑based formulations. By enhancing T‑cell activation and reducing reactogenicity, SLA‑SE addresses long‑standing challenges in immunogenicity, especially for older adults who are most vulnerable to herpes zoster. This technological advance aligns with a broader industry trend where biotech firms prioritize immune‑profile optimization to differentiate pipelines and meet regulatory expectations for safety and efficacy.

Lilly’s acquisition of Curevo’s CRV‑101 underscores the strategic value of integrating cutting‑edge adjuvant platforms into large pharmaceutical portfolios. The Phase‑3‑ready vaccine, now backed by Lilly’s extensive development, manufacturing, and global commercialization capabilities, is poised to capture a sizable share of the U.S. shingles market, projected to exceed $2 billion annually. Beyond revenue potential, the deal accelerates the timeline for bringing a more tolerable, high‑performing shingles vaccine to patients, reinforcing Lilly’s position in the infectious‑disease space.

For AAHI, retaining licensing rights to SLA‑SE opens a multi‑indication revenue engine that could fund its nonprofit mission of affordable vaccine access worldwide. The adjuvant’s applicability to a spectrum of infectious diseases, oncology vaccines, and emerging pathogens positions it as a versatile tool in the post‑pandemic era. As more developers adopt such platforms, the competitive landscape will likely reward those who can swiftly license and integrate advanced adjuvants, driving innovation while expanding global health impact.